Engineered Virus-Like Nanoparticles Enable Multimodal Protein Degradation for Enhanced Tumor Therapy

Area of Science:

• Biotechnology
• Nanomedicine
• Oncology

Background:

• Virus-like particles (VLPs) show potential in drug delivery and cancer therapy but face limitations in stability and versatility.
• Existing protein-based viral mimics struggle with structural integrity and functional adaptability for advanced nanotherapeutics.

Purpose of the Study:

• To engineer a biomimetic virus-like nanoparticle (VNP) platform with enhanced structural stability and multifunctional capabilities.
• To combine gene silencing and targeted protein degradation within a single nanotherapeutic system.
• To overcome the limitations of traditional VLP-based approaches for cancer therapy.

Main Methods:

• Engineered a modular VNP platform integrating lipid scaffolding, siRNA encapsulation, and DNA aptamer-based LYTAC (DbLYTAC).
• Validated VNP efficacy through in vitro experiments assessing targeted protein degradation.
• Evaluated VNP potential in vivo using animal models for tumor therapy.

Main Results:

• The engineered VNPs demonstrated enhanced structural stability and functional versatility.
• In vitro studies confirmed the VNP platform's high efficacy in targeted protein degradation.
• In vivo studies indicated promising therapeutic potential for tumor treatment in animal models.

Conclusions:

• The developed biomimetic VNP platform offers a paradigm shift in nanotherapeutics for cancer treatment.
• This modular design synergistically enhances gene silencing and targeted protein degradation.
• The platform overcomes limitations of protein-based viral mimics, paving the way for advanced multifunctional nanomedicines.